دورية أكاديمية
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
العنوان: | Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin |
---|---|
المؤلفون: | Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki Ito, Hitomi Kaneko, Kazunori Imada, Yuji Shimura, Shin-ichi Fuchida, Kentaro Fukushima, Hirokazu Tanaka, Satoshi Yoshihara, Kensuke Ohta, Nobuhiko Uoshima, Hideo Yagi, Hirohiko Shibayama, Ryosuke Yamamura, Yasuhiro Tanaka, Hitoji Uchiyama, Yoshiyuki Onda, Yoko Adachi, Hitoshi Hanamoto, Ryoichi Takahashi, Mitsuhiro Matsuda, Takashi Miyoshi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda |
المصدر: | Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023) |
بيانات النشر: | Nature Portfolio, 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Medicine LCC:Science |
مصطلحات موضوعية: | Medicine, Science |
الوصف: | Abstract Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29 months (5.18–9.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated κ/λ ratio, lower β2 microglobulin levels (B2MG), fewer prior drug regimens, no prior daratumumab use and better response after elotuzumab treatment. A multivariate analysis showed that TTNT was longer in patients with more lymphocytes (≥ 1400/μL), non-deviated κ/λ ratio (0.1–10), lower B2MG ( |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2045-2322 |
العلاقة: | https://doaj.org/toc/2045-2322Test |
DOI: | 10.1038/s41598-023-32426-6 |
الوصول الحر: | https://doaj.org/article/f9f360c7a7b8496ea74ce32ada6c5c4dTest |
رقم الانضمام: | edsdoj.f9f360c7a7b8496ea74ce32ada6c5c4d |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 20452322 |
---|---|
DOI: | 10.1038/s41598-023-32426-6 |